Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

SAN FRANCISCO—Prime Medicine is on track to file the first IND/CTA application for human trials of a prime editing therapy to the FDA during the first half of this year, with the first clinical data ...

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device ...

Passive Brain-Computer Interfaces (pBCIs) have shown significant advancements in recent years, indicating their readiness for ...

Application denied. That's what regulators with the U.S. Food and Drug Administration (FDA) had to tell Elon Musk's brain implant company, Neuralink, after it sought the green light to begin human ...

JMIR Human Factors (2023 Impact Factor 2.7) Editor-in-Chief: Andre Kushniruk, BA, MSc, PhD, FACMI and Guest Editor: Elizabeth Borycki RN, PhD, FIAHIS, FACMI, FCAHS welcome submissions to a special ...

Prior to completing an application, you will need to satisfy training requirements. The Human Subject Research Orientation on Canvas will ultimately save you time in ...